Literature DB >> 1914376

Influence of menstrual cycle and gender on alprazolam pharmacokinetics.

C Kirkwood1, A Moore, P Hayes, C L DeVane, A Pelonero.   

Abstract

The effects of menstrual cycle phases and gender on alprazolam pharmacokinetics were evaluated in normal volunteers. Alprazolam (1 mg) was administered to seven women during the late follicular and luteal phases of the menstrual cycle and to eight men on one occasion. No difference in alprazolam pharmacokinetic parameters was observed during the menstrual cycle phases. Mean alprazolam clearance (+/- SD) was 0.0037 +/- 0.0009 ml/hr during the follicular phase and 0.0036 +/- 0.001 ml/hr during the luteal phase (p greater than 0.05, difference not significant). With use of weight as a covariant, there was no difference in alprazolam pharmacokinetic parameters between women and men. Mean alprazolam clearance (+/- SD) was 0.0036 +/- 0.0009 ml/hr in women compared with 0.0041 +/- 0.0006 ml/hr in men (p greater than 0.05, difference not significant). Although alprazolam metabolism was similar on the 2 days tested, alterations may occur at other times during the menstrual cycle. Further investigation is needed to understand the effects of menstrual cycle phases and gender on drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914376     DOI: 10.1038/clpt.1991.157

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.

Authors:  M Hossain; E Wright; R Baweja; T Ludden; R Miller
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 2.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs.

Authors:  A D Kashuba; A N Nafziger
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

Review 4.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women.

Authors:  Charles E Frost; John Adams; Mark Shelton; Abdel-Hameed I Mohammed Ebid; Lawrence J Gugino; Ross Hewitt; Robin Difrancesco; Elizabeth Ingalls; Stephen Cousins; J Hu; Gene D Morse
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

Review 6.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

8.  Sex-dependent modulation of treatment response.

Authors:  David R Rubinow; Molly Moore
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

9.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

Review 10.  The influence of sex on pharmacokinetics.

Authors:  Janice B Schwartz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 5.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.